Visiting Professor of Pharmacology, Department of Medicine.
Until retirement in April 2008 Professor Hill was Executive Director, Licensing and External Research, Europe for Merck, Sharp and Dohme Research Laboratories. He worked in the pharmaceutical industry for over 25 years. Between 1997 and 2002 he had oversight responsibility for Neuroscience research at the MSD / Banyu Research Labs in Tsukuba, Japan. At Merck he chaired discovery project teams responsible for the marketed products Maxalt® and Emend®.
Dr. Hill is a non-executive director of Avilex, Asceneuron, Covagen (until its sale to J&J in Sept 2014) and of Orexo AB. He is Visiting Industrial Professor of Pharmacology in the University of Bristol. Dr Hill received BPharm and PhD degrees from the University of London and was elected to Fellowship of the Academy of Medical Sciences in 2005 . He was a lecturer in Pharmacology at the University of Bristol School of Medicine from 1974 to 1983. He is President Emeritus of the British Pharmacological Society, a member of Finance Committee, Academy of Medical Sciences and serves on the UK Advisory Council on Misuse of Drugs.
Telephone: +44 (0)7872 850 331